Meeting
2022 ASCO Annual Meeting
Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.
Authors
Huizi Lei
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Huizi Lei , Yun Ling , Pei Yuan , Jun Guo , Xinan Sheng , Ai-Ping Zhou , Jianming Ying
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4572)
DOI
10.1200/JCO.2022.40.16_suppl.4572
Abstract #
4572
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
HER2 gene amplification and protein overexpression in uterine clear cell carcinoma and its implications in targeted immunotherapy.
First Author: Jain Zhou
Poster
2015 ASCO Annual Meeting
Defining the spectrum and "overlap" of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation.
First Author: Bob T. Li
First Author: Robert D. Loberg
Poster
2014 ASCO Annual Meeting
Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper gastrointestinal (UGI) adenocarcinomas.
First Author: Michael F. Press